Health

OS Win for Enzalutamide in Prostate Cancer at High Risk for Biochemical Recurrence

TribeNews
By TribeNews 1 View Add a Comment
0 Min Read
OS Win for Enzalutamide in Prostate Cancer at High Risk for Biochemical Recurrence

MedPage Today) — BERLIN — Combining enzalutamide (Xtandi) with androgen deprivation therapy (ADT) significantly improved overall survival (OS) in patients with prostate cancer at high risk for biochemical recurrence, according to results from…

Leave a Comment
Ads Blocker Image Powered by Code Help Pro

Ads Blocker Detected & This Is Prohibited!!!

We have detected that you are using extensions to block ads and you are also not using our official app. Your Account Have been Flagged and reported, pending de-activation & All your earning will be wiped out. Please turn off the software to continue

You cannot copy content of this app